Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer

Lung Cancer

Volumn 101, Issue , 2016, Pages 92-97

  Suzuki, Yuzo ^a   Okamoto, Tatsuro ^a   Fujishita, Takatoshi ^a   Katsura, Masakazu ^a   Akamine, Takaki ^a   Takamori, Shinkichi ^a   Morodomi, Yosuke ^a   Tagawa, Tetsuzo ^a   Shoji, Fumihiro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Computed tomography; Non small cell lung cancer; Prognosis; Sarcopenia

Indexed keywords

AGED; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PATIENT; PRIORITY JOURNAL; SARCOPENIA; SKELETAL MUSCLE; THIRD LUMBAR VERTEBRA; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; DIAGNOSTIC IMAGING; LUNG NEOPLASMS; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; X-RAY COMPUTED TOMOGRAPHY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RETROSPECTIVE STUDIES; SARCOPENIA; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84989186833     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.08.007     Document Type: Article

References (27)

1. [1] Goldstraw, P., Crowley, J., Chansky, K., Giroux, D.J., Groome, P.A., Rami-Porta, R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thorac. Oncol. 2 (2007), 706–714.
2. [2] Sawabata, N., Miyaoka, E., Asamura, H., Nakanishi, Y., Eguchi, K., Mori, M., et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J. Thorac. Oncol. 6 (2011), 1229–1235.
3. [3] Kawaguchi, T., Takada, M., Kubo, A., Matsumura, A., Fukai, S., Tamura, A., et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J. Thorac. Oncol. 5 (2010), 620–630.
4. [4] Attaran, S., McShane, J., Whittle, I., Poullis, M., Shackcloth, M., A propensity-matched comparison of survival after lung resection in patients with a high versus low body mass index. Eur. J. Cardiothorac. Surg. 42 (2012), 653–658.
5. [5] Jagoe, R.T., Goodship, T.H., Gibson, G.J., The influence of nutritional status on complications after operations for lung cancer. Ann. Thorac. Surg. 71 (2001), 936–943.
6. [6] Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., et al. Sarcopenia: European consensus on definition and diagnosis: report of the european working group on sarcopenia in older people. Age Ageing 39 (2010), 412–423.
7. [7] International agency for research on cancer, Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 2004, IARC Press, Lyon, France.
8. [8] International Union Against Cancer. The TNM Classification of Malignant Tumors, 7th Edition. 2009.
9. [9] Harimoto, N., Shirabe, K., Yamashita, Y.I., Ikegami, T., Yoshizumi, T., Soejima, Y., et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br. J. Surg. 100 (2013), 1523–1530.
10. [10] van Vledder, M.G., Levolger, S., Ayez, N., Verhoef, C., Tran, T.C., Ijzermans, J.N., Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br. J. Surg. 99 (2012), 550–557.
11. [11] Harvie, M.N., Campbell, I.T., Thatcher, N., Baildam, A., Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy. J. Hum. Nutr. Diet 16 (2003), 323–326.
12. [12] Prado, C.M., Baracos, V.E., McCargar, L.J., Mourtzakis, M., Mulder, K.E., Reiman, T., et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin. Cancer Res. 13 (2007), 3264–3268.
13. [13] Barret, M., Antoun, S., Dalban, C., Malka, D., Mansourbakht, T., Zaanan, A., et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr. Cancer 66 (2014), 583–589.
14. [14] Prado, C.M., Baracos, V.E., McCargar, L.J., Reiman, T., Mourtzakis, M., Tonkin, K., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 15 (2009), 2920–2926.
15. [15] Iritani, S., Imai, K., Takai, K., Hanai, T., Ideta, T., Miyazaki, T., et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J. Gastroenterol. 50 (2015), 323–332.
16. [16] Collins, J., Noble, S., Chester, J., Coles, B., Byrne, A., The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open, 4, 2014, e003697.
17. [17] Prado, C.M., Lieffers, J.R., McCargar, L.J., Reiman, T., Sawyer, M.B., Martin, L., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9 (2008), 629–635.
18. [18] Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31 (2013), 1539–1547.
19. [19] Kovarik, M., Hronek, M., Zadak, Z., Clinically relevant determinants of body composition, function and nutritional status as mortality predictors in lung cancer patients. Lung Cancer 84 (2014), 1–6.
20. [20] Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12 (2011), 489–495.
21. [21] van der Meij, B.S., Schoonbeek, C.P., Smit, E.F., Muscaritoli, M., van Leeuwen, P.A., Langius, J.A., Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks. Br. J. Nutr. 109 (2013), 2231–2239.
22. [22] Prado, C.M., Sawyer, M.B., Ghosh, S., Lieffers, J.R., Esfandiari, N., Antoun, S., et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential. Am. J. Clin. Nutr. 98 (2013), 1012–1019.
23. [23] James, F.R., Wootton, S., Jackson, A., Wiseman, M., Copson, E.R., Cutress, R.I., Obesity in breast cancer–what is the risk factor?. Eur. J. Cancer 51 (2015), 705–720.
24. [24] Palomares, M.R., Sayre, J.W., Shekar, K.C., Lillington, L.M., Chlebowski, R.T., Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 78 (1996), 2119–2126.
25. [25] Chansky, K., Sculier, J.P., Crowley, J.J., Giroux, D., Van Meerbeeck, J., Goldstraw, P., et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J. Thorac. Oncol. 4 (2009), 792–801.
26. [26] Van Cutsem, E., Arends, J., The causes and consequences of cancer-associated malnutrition. Eur. J. Oncol. Nurs. 9:Suppl. 2 (2005), S51–S63.
27. [27] Faber, J., Uitdehaag, M.J., Spaander, M., van Steenbergen-Langeveld, S., Vos, P., Berkhout, M., et al. Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J. Cachexia Sarcopenia Muscle 6 (2015), 32–34.